
KIM FOREST — Investor Relations & Filings
Kim Forest Enterprise Co., Ltd. specializes in precision medicine and molecular diagnostics, providing integrated solutions for clinical research and healthcare. The company offers a "One Stop Solution" encompassing experimental consultation, laboratory equipment supply, and bioinformatics analysis. Key products and services include Next-Generation Sequencing (NGS), PCR systems, ELISA readers, and high-content imaging systems. The company focuses on genetic testing for cancer screening, hereditary diseases, and personalized health management. By synthesizing genomic data with clinical insights, Kim Forest facilitates biomarker identification and the development of optimized treatment strategies. Its portfolio also extends to customized enzymes, drug screening technologies, and precision nutrition, supporting the advancement of personalized medicine through comprehensive technical expertise and reliable diagnostic reporting.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年第1季財務報告書 — 202601_6645_AI1.pdf | 2026-05-11 | Chinese | |
| 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | |
| 115年04月董事會成員及持股 | 2026-05-05 | Chinese | |
| 公告本公司115年第一季財務報告董事會 預計召開日期為115年05月08日 | 2026-04-30 | Chinese | |
| 114年第4季財務報告書 — 202504_6645_AIC.pdf | 2026-04-21 | Chinese | |
| 114年第4季財務報告書 — 202504_6645_AIA.pdf | 2026-04-21 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45580484 | 115年第1季財務報告書 — 202601_6645_AI1.pdf | 2026-05-11 | Chinese | ||
| 41459706 | 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | ||
| 41457341 | 115年04月董事會成員及持股 | 2026-05-05 | Chinese | ||
| 39887117 | 公告本公司115年第一季財務報告董事會 預計召開日期為115年05月08日 | 2026-04-30 | Chinese | ||
| 34695803 | 114年第4季財務報告書 — 202504_6645_AIC.pdf | 2026-04-21 | Chinese | ||
| 34695802 | 114年第4季財務報告書 — 202504_6645_AIA.pdf | 2026-04-21 | Chinese | ||
| 34695801 | 114年第4季財務報告書 — 202504_6645_AI3.pdf | 2026-04-21 | Chinese | ||
| 34695800 | 114年第4季財務報告書 — 202504_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34695799 | 114年第4季財務報告書 — 202503_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34695798 | 114年第4季財務報告書 — 202502_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34695797 | 114年第4季財務報告書 — 202501_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34690456 | 114年年報及股東會資料 — 2026_6645_20260522F17.pdf | 2026-04-20 | Chinese | ||
| 34690455 | 114年年報及股東會資料 — 2025_6645_20260522FE4.pdf | 2026-04-20 | English | ||
| 34690454 | 114年年報及股東會資料 — 2025_6645_20260522F04.pdf | 2026-04-20 | Chinese | ||
| 34690442 | 114年年報及股東會資料 — 2026_6645_20260522F02.pdf | 2026-04-20 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMAGION BIOSYSTEMS LIMITED
Develops nanoparticle-based imaging for non-invasive cancer…
|
IBX | AU | Professional, scientific and te… |
|
IMCB PJSC
Biotechnology company specializing in personal stem cell ba…
|
GEMA | RU | Professional, scientific and te… |
|
Immuneering Corp
Clinical-stage oncology company developing medicines using …
|
IMRX | US | Professional, scientific and te… |
|
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Clinical-stage biotech developing dual-approach immuno-onco…
|
1541 | HK | Professional, scientific and te… |
|
IMMUNIC, INC.
Develops oral small molecule therapies for chronic inflamma…
|
IMUX | US | Professional, scientific and te… |
|
Immunovant, Inc.
Clinical-stage immunology company developing anti-FcRn anti…
|
IMVT | US | Professional, scientific and te… |
|
IMMUPHARMA PLC
Specialty biopharmaceutical company developing peptide-base…
|
IMM | GB | Professional, scientific and te… |
|
IMMUTEP LIMITED
Develops LAG-3 targeting immunotherapies for cancer and aut…
|
IMM | AU | Professional, scientific and te… |
|
IMMUTEP Ltd
Biotechnology company developing LAG-3 immunotherapies for …
|
IMMP | US | Professional, scientific and te… |
|
IMPACT BIOMEDICAL INC.
Develops biopharmaceutical products and technologies to pro…
|
IBO | US | Professional, scientific and te… |
KIM FOREST via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52599/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52599 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52599 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52599 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52599}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for KIM FOREST (id: 52599)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.